| Patient | Lorraine Hansberry |
|---|---|
| Date of birth | 1993-05-19 |
| Identifiers | MRN HR-ML034-SYN; SSN (made up) 000-34-7158 |
| Document date | 2026-11-01 |
| Author | Odette Marchetti-Fields, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two months of epigastric and back pain, weight loss, black stools and near-fainting in a woman of 32: examination, blood tests, and urgent upper endoscopy and pancreas-protocol CT. Concerns: Burning, boring pain under the breastbone and through to the back for about two months, worse after meals and at night; black stools on and off for three weeks; two near-fainting spells; weight down 5 kg; An urgent care clinic put the pain down to indigestion and stress five weeks ago; she does not want it put down to stress again, and wants the cause found and told to her plainly, whatever it is; She wants to finish her play and to keep writing through whatever treatment she needs, with a clear head. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfast | One tablet daily before breakfast | Oral route | 2026-04-20 | active | S |
| Ferric carboxymaltose 50 mg/mL injection, 750 mg intravenously, two doses one week apart | 750 mg intravenously; two doses one week apart | Intravenous route | 2026-04-24 to 2026-05-01 | completed | S |
| Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for pain | One tablet every 4 hours as needed | Oral route | 2026-05-04 | active | S |
| Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodone | Two tablets at night | Oral route | 2026-05-04 | active | S |
| Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snack | Two capsules with each meal, one with each snack | Oral route | 2026-05-04 to 2026-10-05 | completed | S |
| Oxaliplatin 5 mg/mL injection, 135 mg (85 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cycles | Day 1 every 14 days for six cycles | Intravenous route | 2026-05-18 to 2026-07-27 | completed | S |
| Irinotecan 20 mg/mL injection, 238 mg (150 mg/m2) intravenously over 90 minutes on day 1 of each 14-day cycle, cycles 1 to 5 | Day 1 every 14 days, cycles 1 to 5 | Intravenous route | 2026-05-18 to 2026-07-13 | completed | S |
| Irinotecan 20 mg/mL injection, 190 mg (120 mg/m2, one dose level lower) intravenously on day 1 of cycle 6 | Day 1 of cycle 6 | Intravenous route | 2026-07-27 to 2026-07-27 | completed | S |
| Leucovorin 10 mg/mL injection, 634 mg (400 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cycles | Day 1 every 14 days for six cycles | Intravenous route | 2026-05-18 to 2026-07-27 | completed | S |
| Fluorouracil 50 mg/mL injection, 3800 mg (2400 mg/m2) by continuous infusion over 46 hours through the port from day 1 of each 14-day cycle, for six cycles, with no bolus | 46-hour infusion from day 1 every 14 days for six cycles | Intravenous route | 2026-05-18 to 2026-07-29 | completed | S |
| Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle, after the pump is disconnected | 6 mg on day 3 of each cycle | Subcutaneous route | 2026-05-20 to 2026-07-29 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet every 8 hours as needed | Oral route | 2026-05-18 | active | S |
| Olanzapine 5 mg oral tablet, one tablet by mouth at night on days 1 to 4 of each cycle | One tablet at night on days 1 to 4 | Oral route | 2026-05-18 | active | S |
| Loperamide 2 mg oral capsule, two capsules at the first loose stool, then one after each loose stool, no more than eight a day unless directed | 4 mg at onset, then 2 mg after each loose stool | Oral route | 2026-05-18 | active | S |
| Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy, stopped three days before surgery | One tablet twice daily | Oral route | 2026-06-29 to 2026-08-21 | completed | S |
| Potassium chloride 20 mEq extended-release tablet, two tablets by mouth today, then one tablet daily for three days | 40 mEq today, then 20 mEq daily for three days | Oral route | 2026-07-16 to 2026-07-19 | completed | S |
| Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery | 40 mg once daily for 28 days | Subcutaneous route | 2026-08-24 to 2026-09-21 | completed | S |
| Insulin glargine 100 units/mL pen, 8 units under the skin at night | 8 units at night | Subcutaneous route | 2026-08-28 to 2026-10-05 | completed | S |
| Insulin glargine 100 units/mL pen, 10 units under the skin at night | 10 units at night | Subcutaneous route | 2026-10-05 | active | S |
| Pancrelipase delayed-release capsule (lipase 36,000 units), three capsules with each meal and two with each snack | Three capsules with each meal, two with each snack | Oral route | 2026-10-05 | active | S |
| Irinotecan 20 mg/mL injection, 184 mg (120 mg/m2) intravenously on day 1 of each 14-day cycle, for six cycles after surgery | Day 1 every 14 days for six cycles | Intravenous route | 2026-10-12 | active | S |
| Leucovorin 10 mg/mL injection, 612 mg (400 mg/m2) intravenously on day 1 of each 14-day cycle, for six cycles after surgery | Day 1 every 14 days for six cycles | Intravenous route | 2026-10-12 | active | S |
| Fluorouracil 50 mg/mL injection, 3670 mg (2400 mg/m2) by continuous infusion over 46 hours from day 1 of each 14-day cycle, for six cycles after surgery | 46-hour infusion from day 1 every 14 days for six cycles | Intravenous route | 2026-10-12 | active | S |
| Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle after surgery | 6 mg on day 3 of each cycle | Subcutaneous route | 2026-10-14 | active | S |
| Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy after surgery | One tablet twice daily | Oral route | 2026-10-12 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Upper endoscopy with biopsy, under sedation: no gastric or duodenal ulcer; a friable, ulcerated mass on the medial wall of the second part of the duodenum next to the major papilla, oozing slowly; four biopsies taken; hemostasis with epinephrine injection | 2026-04-22 to 2026-04-22 | completed | S |
| Pancreas-protocol CT of the abdomen and pelvis with contrast (arterial and portal venous phases), with CT of the chest: a 3.1 cm hypoattenuating mass in the head of the pancreas invading the duodenal wall; dilated common bile duct (13 mm) and pancreatic duct (5 mm); tumor contact with about 200 degrees of the superior mesenteric vein with short-segment narrowing that can be reconstructed; no contact with the superior mesenteric artery, celiac axis or common hepatic artery; no liver, peritoneal or lung lesion; no ascites | 2026-04-23 to 2026-04-23 | completed | S |
| Endoscopic ultrasound with fine-needle biopsy of the pancreatic head mass (three passes with a 22-gauge biopsy needle): 3.2 cm hypoechoic mass invading the duodenum and abutting the portal confluence; no ascites; rapid on-site evaluation adequate; extra cores sent for tumor molecular profiling | 2026-04-27 to 2026-04-27 | completed | S |
| ERCP in the same session with placement of a fully covered self-expanding metal stent (10 mm by 60 mm) across a distal common bile duct stricture; good drainage of bile | 2026-04-27 to 2026-04-27 | completed | S |
| Pancreatic multidisciplinary tumor board (surgical oncology, medical oncology, radiation oncology, gastroenterology, radiology, pathology, palliative care, nurse navigator): borderline resectable pancreatic head adenocarcinoma (venous involvement); recommends chemotherapy before surgery with modified FOLFIRINOX, restaging, then resection if there is no progression | 2026-04-29 to 2026-04-29 | completed | S |
| Advance care planning conversation, about 30 minutes | 2026-10-21 to 2026-10-21 | completed | S |
| Genetic counseling before germline testing: three-generation pedigree, consent, and explanation of what a positive or negative result would mean for her and her blood relatives | 2026-05-04 to 2026-05-04 | completed | S |
| Outpatient palliative care consultation, two days after the diagnosis visit: symptom review, a serious illness conversation about her hopes, worries and what matters most (her writing and a clear head), and a plan for pain, appetite and sleep alongside cancer treatment | 2026-05-06 to 2026-05-06 | completed | S |
| Restaging pancreas-protocol CT of the abdomen and pelvis with contrast, with CT of the chest, after six cycles: pancreatic head mass smaller (2.1 cm from 3.1 cm); contact with the superior mesenteric vein reduced to about 150 degrees; no arterial contact; biliary stent in place; no liver, peritoneal or lung lesion | 2026-08-06 to 2026-08-06 | completed | S |
| Open pylorus-preserving pancreaticoduodenectomy with segmental resection of the superior mesenteric vein and primary venous repair, and removal of the biliary stent: pathology ypT2N1 (2.3 cm residual adenocarcinoma; 2 of 18 lymph nodes involved; perineural invasion), all margins clear (R0), partial treatment response (CAP tumor regression score 2); nine days in hospital, with mild delayed gastric emptying that settled | 2026-08-24 to 2026-08-24 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2022-09-12 | Tdap vaccine | completed | S |
| 2026-05-04 | Pneumococcal conjugate vaccine (PCV20), before chemotherapy | completed | S |
| 2026-05-04 | Recombinant zoster vaccine, dose 1 of 2, before chemotherapy | completed | S |
| 2026-06-29 | Recombinant zoster vaccine, dose 2 of 2 | completed | S |
| 2026-10-21 | Influenza vaccine, this season (inactivated) | completed | S |
| 2026-10-21 | COVID-19 mRNA vaccine, this season's formula | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
No historical medical events are recorded.
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | Died suddenly of a cerebral hemorrhage when she was sixteen; no cancer recorded in the cited source | D (CLM-0003) |
| Concern | Status | Evidence |
|---|---|---|
| Burning, boring pain under the breastbone and through to the back for about two months, worse after meals and at night; black stools on and off for three weeks; two near-fainting spells; weight down 5 kg | active | S |
| An urgent care clinic put the pain down to indigestion and stress five weeks ago; she does not want it put down to stress again, and wants the cause found and told to her plainly, whatever it is | active | S |
| She wants to finish her play and to keep writing through whatever treatment she needs, with a clear head | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 10.6 on 2026-10-05; MCV [Entitic mean volume] in Red Blood Cells by Automated count 74 on 2026-04-20; Leukocytes [#/volume] in Blood by Automated count 8.2 on 2026-10-05; Platelets [#/volume] in Blood by Automated count 302 on 2026-10-05; Ferritin [Mass/volume] in Serum or Plasma 88 on 2026-06-29; Sodium [Moles/volume] in Serum or Plasma 137 on 2026-10-05; Potassium [Moles/volume] in Serum or Plasma 4.3 on 2026-10-05; Creatinine [Mass/volume] in Serum or Plasma 0.71 on 2026-10-05; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 116 on 2026-10-05; Glucose [Mass/volume] in Serum or Plasma 156 on 2026-10-05; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 2026-10-05; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 2026-10-05; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 110 on 2026-10-05; Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 on 2026-10-05; Albumin [Mass/volume] in Serum or Plasma 3.4 on 2026-10-05; Lipase [Enzymatic activity/volume] in Serum or Plasma 52 on 2026-04-20; Hemoglobin A1c/Hemoglobin.total in Blood 7 on 2026-08-10; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-04-20; Pain severity - 0-10 verbal numeric rating [Score] - Reported 2 on 2026-10-05; Neutrophils [#/volume] in Blood by Automated count 5.1 on 2026-10-05; Cancer Ag 19-9 [Units/volume] in Serum or Plasma 18 on 2026-10-05; Carcinoembryonic Ag [Mass/volume] in Serum or Plasma 3.9 on 2026-05-04; INR in Platelet poor plasma by Coagulation assay 1 on 2026-08-10; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 on 2026-10-21; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 6 on 2026-10-05; Magnesium [Mass/volume] in Serum or Plasma 1.6 on 2026-07-16; Albumin/Creatinine [Mass Ratio] in Urine 12 on 2026-10-05 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this week | resolved | confirmed | R10.13 | S — Synthetic presenting problem anchored to the documented collapse in pain and the account of a suspected duodenal ulcer. Superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mL | active | confirmed | D50.0 | S — Synthetic finding anchored to the documented account that she was told she had anemia and bleeding ulcers. |
| New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2 | resolved | confirmed | R73.09 | S — Synthetic finding; superseded when diabetes due to the pancreatic cancer was recorded at the second visit. |
| Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differently | active | confirmed | C25.0 | S — Synthetic histology, site, stage and course; the sources say she died of cancer and differ on whether it was pancreatic, duodenal, or colonic with spread to the pancreas (R). See sources.md. |
| Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dL | active | confirmed | E08.9 | S — Synthetic consequence of the synthetic tumor. |
| Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight loss | active | confirmed | K86.81 | S — Synthetic consequence of the synthetic tumor; diagnosed clinically, as guidance allows in pancreatic cancer. |
| Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by it | active | confirmed | G89.3 | S — Synthetic symptom of the synthetic tumor. |
| Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCP | resolved | confirmed | K83.1 | S — Synthetic consequence of the synthetic tumor. |
| Chemotherapy-induced diarrhea from irinotecan, grade 2 (five to six watery stools a day above her usual), starting on day 3 of cycle 5, with low potassium and magnesium and mild dehydration; no fever, blood or neutropenia; resolved | resolved | confirmed | K52.1 | S — Synthetic treatment effect; not a historical claim. |
| Oxaliplatin peripheral neuropathy, grade 1: tingling in the fingers and toes in the cold, lasting a few days after each cycle, with mild tingling at the fingertips between cycles; no effect on writing or buttons | active | confirmed | G62.0 | S — Synthetic common effect of oxaliplatin. |
| After pylorus-preserving pancreaticoduodenectomy with superior mesenteric vein resection: loss of the head of the pancreas, with more marked exocrine insufficiency and insulin-requiring diabetes | active | confirmed | Z90.411 | S — Synthetic consequence of the synthetic operation. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-20 | Hemoglobin [Mass/volume] in Blood | 9.1 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-04-20 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 74 | fL | 80-100 fL | Low | S |
| 2026-04-20 | Leukocytes [#/volume] in Blood by Automated count | 7.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-04-20 | Platelets [#/volume] in Blood by Automated count | 388 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-04-20 | Ferritin [Mass/volume] in Serum or Plasma | 6 | ng/mL | 15-150 ng/mL | Low | S |
| 2026-04-20 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-20 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-20 | Creatinine [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-04-20 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 118 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-20 | Glucose [Mass/volume] in Serum or Plasma | 132 | mg/dL | 70-99 mg/dL | High | S |
| 2026-04-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 48 | U/L | 7-35 U/L | High | S |
| 2026-04-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 41 | U/L | 8-35 U/L | High | S |
| 2026-04-20 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 236 | U/L | 35-104 U/L | High | S |
| 2026-04-20 | Bilirubin.total [Mass/volume] in Serum or Plasma | 1.6 | mg/dL | 0.1-1.2 mg/dL | High | S |
| 2026-04-20 | Albumin [Mass/volume] in Serum or Plasma | 3.6 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-04-20 | Lipase [Enzymatic activity/volume] in Serum or Plasma | 52 | U/L | 13-60 U/L | Normal | S |
| 2026-04-20 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.6 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes | High | S |
| 2026-04-20 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-04-20 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 5 | {score} | S | ||
| 2026-05-04 | Hemoglobin [Mass/volume] in Blood | 10.4 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-05-04 | Leukocytes [#/volume] in Blood by Automated count | 7 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-05-04 | Neutrophils [#/volume] in Blood by Automated count | 4.6 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-05-04 | Platelets [#/volume] in Blood by Automated count | 366 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-05-04 | Creatinine [Mass/volume] in Serum or Plasma | 0.68 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-05-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 119 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-04 | Glucose [Mass/volume] in Serum or Plasma | 141 | mg/dL | 70-99 mg/dL | High | S |
| 2026-05-04 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-35 U/L | Normal | S |
| 2026-05-04 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 8-35 U/L | Normal | S |
| 2026-05-04 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 168 | U/L | 35-104 U/L | High | S |
| 2026-05-04 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-05-04 | Albumin [Mass/volume] in Serum or Plasma | 3.5 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-05-04 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 486 | U/mL | <=35 U/mL | High | S |
| 2026-05-04 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 3.9 | ng/mL | Up to 3.0 ng/mL in non-smokers | High | S |
| 2026-05-04 | INR in Platelet poor plasma by Coagulation assay | 1 | {INR} | 0.8-1.2 | Normal | S |
| 2026-05-04 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-05-04 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | S | ||
| 2026-05-04 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 6 | {score} | S | ||
| 2026-06-29 | Hemoglobin [Mass/volume] in Blood | 11.2 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-06-29 | Leukocytes [#/volume] in Blood by Automated count | 8.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-06-29 | Neutrophils [#/volume] in Blood by Automated count | 5.8 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-06-29 | Platelets [#/volume] in Blood by Automated count | 214 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-29 | Creatinine [Mass/volume] in Serum or Plasma | 0.72 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-06-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 114 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-29 | Glucose [Mass/volume] in Serum or Plasma | 128 | mg/dL | 70-99 mg/dL | High | S |
| 2026-06-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-35 U/L | Normal | S |
| 2026-06-29 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 8-35 U/L | Normal | S |
| 2026-06-29 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 120 | U/L | 35-104 U/L | High | S |
| 2026-06-29 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-06-29 | Albumin [Mass/volume] in Serum or Plasma | 3.5 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-06-29 | Magnesium [Mass/volume] in Serum or Plasma | 1.9 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 2026-06-29 | Ferritin [Mass/volume] in Serum or Plasma | 88 | ng/mL | 15-150 ng/mL | Normal | S |
| 2026-06-29 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 210 | U/mL | <=35 U/mL | High | S |
| 2026-06-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-06-29 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 9 | {score} | S | ||
| 2026-06-29 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | {score} | S | ||
| 2026-07-16 | Hemoglobin [Mass/volume] in Blood | 11 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-07-16 | Leukocytes [#/volume] in Blood by Automated count | 6.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-07-16 | Neutrophils [#/volume] in Blood by Automated count | 4.1 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-07-16 | Platelets [#/volume] in Blood by Automated count | 188 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-07-16 | Sodium [Moles/volume] in Serum or Plasma | 134 | mmol/L | 135-145 mmol/L | Low | S |
| 2026-07-16 | Potassium [Moles/volume] in Serum or Plasma | 3.2 | mmol/L | 3.5-5.1 mmol/L | Low | S |
| 2026-07-16 | Creatinine [Mass/volume] in Serum or Plasma | 0.94 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-07-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 83 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-16 | Glucose [Mass/volume] in Serum or Plasma | 118 | mg/dL | 70-99 mg/dL | High | S |
| 2026-07-16 | Magnesium [Mass/volume] in Serum or Plasma | 1.6 | mg/dL | 1.7-2.2 mg/dL | Low | S |
| 2026-08-10 | Hemoglobin [Mass/volume] in Blood | 10.9 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-08-10 | Leukocytes [#/volume] in Blood by Automated count | 7.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-08-10 | Neutrophils [#/volume] in Blood by Automated count | 4.9 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-08-10 | Platelets [#/volume] in Blood by Automated count | 176 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-08-10 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-08-10 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-10 | Creatinine [Mass/volume] in Serum or Plasma | 0.76 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-08-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 107 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-08-10 | Glucose [Mass/volume] in Serum or Plasma | 124 | mg/dL | 70-99 mg/dL | High | S |
| 2026-08-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-35 U/L | Normal | S |
| 2026-08-10 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 8-35 U/L | Normal | S |
| 2026-08-10 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 98 | U/L | 35-104 U/L | Normal | S |
| 2026-08-10 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-08-10 | Albumin [Mass/volume] in Serum or Plasma | 3.6 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-08-10 | Hemoglobin A1c/Hemoglobin.total in Blood | 7 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes | High | S |
| 2026-08-10 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 41 | U/mL | <=35 U/mL | High | S |
| 2026-08-10 | INR in Platelet poor plasma by Coagulation assay | 1 | {INR} | 0.8-1.2 | Normal | S |
| 2026-08-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-08-10 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 1 | {score} | S | ||
| 2026-10-05 | Hemoglobin [Mass/volume] in Blood | 10.6 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-10-05 | Leukocytes [#/volume] in Blood by Automated count | 8.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-05 | Neutrophils [#/volume] in Blood by Automated count | 5.1 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-10-05 | Platelets [#/volume] in Blood by Automated count | 302 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-05 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-05 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-05 | Creatinine [Mass/volume] in Serum or Plasma | 0.71 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-10-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 116 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-05 | Glucose [Mass/volume] in Serum or Plasma | 156 | mg/dL | 70-99 mg/dL | High | S |
| 2026-10-05 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-35 U/L | Normal | S |
| 2026-10-05 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 8-35 U/L | Normal | S |
| 2026-10-05 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 110 | U/L | 35-104 U/L | High | S |
| 2026-10-05 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-10-05 | Albumin [Mass/volume] in Serum or Plasma | 3.4 | g/dL | 3.5-5 g/dL | Low | S |
| 2026-10-05 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 18 | U/mL | <=35 U/mL | Normal | S |
| 2026-10-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-10-05 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S | ||
| 2026-10-05 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | {score} | S | ||
| 2026-10-21 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-10-05 | Albumin/Creatinine [Mass Ratio] in Urine | 12 | mg/g | <=30 mg/g | Normal | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-20 | Body height | 163 | cm | S |
| 2026-04-20 | Body weight | 56.2 | kg | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 21.2 | kg/m2 | S |
| 2026-04-20 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-04-20 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-04-20 | Heart rate | 102 | /min | S |
| 2026-04-20 | Respiratory rate | 16 | /min | S |
| 2026-04-20 | Body temperature | 36.8 | Cel | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-05-04 | Body height | 163 | cm | S |
| 2026-05-04 | Body weight | 55.4 | kg | S |
| 2026-05-04 | Body mass index (BMI) [Ratio] | 20.9 | kg/m2 | S |
| 2026-05-04 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-05-04 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-05-04 | Heart rate | 92 | /min | S |
| 2026-05-04 | Respiratory rate | 16 | /min | S |
| 2026-05-04 | Body temperature | 36.7 | Cel | S |
| 2026-05-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-06-29 | Body height | 163 | cm | S |
| 2026-06-29 | Body weight | 54.8 | kg | S |
| 2026-06-29 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 2026-06-29 | Systolic blood pressure | 110 | mm[Hg] | S |
| 2026-06-29 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-06-29 | Heart rate | 84 | /min | S |
| 2026-06-29 | Respiratory rate | 16 | /min | S |
| 2026-06-29 | Body temperature | 36.6 | Cel | S |
| 2026-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-08-10 | Body height | 163 | cm | S |
| 2026-08-10 | Body weight | 54.2 | kg | S |
| 2026-08-10 | Body mass index (BMI) [Ratio] | 20.4 | kg/m2 | S |
| 2026-08-10 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-08-10 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-08-10 | Heart rate | 80 | /min | S |
| 2026-08-10 | Respiratory rate | 16 | /min | S |
| 2026-08-10 | Body temperature | 36.6 | Cel | S |
| 2026-08-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-10-05 | Body height | 163 | cm | S |
| 2026-10-05 | Body weight | 51.8 | kg | S |
| 2026-10-05 | Body mass index (BMI) [Ratio] | 19.5 | kg/m2 | S |
| 2026-10-05 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-10-05 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-10-05 | Heart rate | 86 | /min | S |
| 2026-10-05 | Respiratory rate | 16 | /min | S |
| 2026-10-05 | Body temperature | 36.7 | Cel | S |
| 2026-10-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-07-16 | Body height | 163 | cm | S |
| 2026-07-16 | Body weight | 53.6 | kg | S |
| 2026-07-16 | Body mass index (BMI) [Ratio] | 20.2 | kg/m2 | S |
| 2026-07-16 | Systolic blood pressure | 98 | mm[Hg] | S |
| 2026-07-16 | Diastolic blood pressure | 62 | mm[Hg] | S |
| 2026-07-16 | Heart rate | 104 | /min | S |
| 2026-07-16 | Respiratory rate | 16 | /min | S |
| 2026-07-16 | Body temperature | 37.1 | Cel | S |
| 2026-07-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-10-21 | Body height | 163 | cm | S |
| 2026-10-21 | Body weight | 52.4 | kg | S |
| 2026-10-21 | Body mass index (BMI) [Ratio] | 19.7 | kg/m2 | S |
| 2026-10-21 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-10-21 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-10-21 | Heart rate | 84 | /min | S |
| 2026-10-21 | Respiratory rate | 14 | /min | S |
| 2026-10-21 | Body temperature | 36.6 | Cel | S |
| 2026-10-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-04-20 | Two months of epigastric and back pain, weight loss, black stools and near-fainting in a woman of 32: examination, blood tests, and urgent upper endoscopy and pancreas-protocol CT | finished | S |
| 2026-05-04 | Diagnosis of pancreatic adenocarcinoma: tumor board plan, medical oncology consultation, genetic counseling, early palliative care, and planning of chemotherapy before surgery | finished | S |
| 2026-06-29 | Day 1 of cycle 4 of modified FOLFIRINOX: toxicity review, genetic and tumor profiling results, thromboprophylaxis, nutrition and mood | finished | S |
| 2026-08-10 | After six cycles: restaging CT and CA 19-9, decision for surgery, and preparation for pancreaticoduodenectomy | finished | S |
| 2026-10-05 | Six weeks after pancreaticoduodenectomy: pathology, diabetes and enzyme replacement after surgery, and the plan for chemotherapy after surgery | finished | S |
| 2026-07-16 | Same-day sick visit for diarrhea during chemotherapy | finished | S |
| 2026-10-21 | Periodic adult preventive visit during chemotherapy after surgery | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Medical oncology consultation within two weeks to review the endoscopy, CT and any biopsy with her and plan treatment if cancer is found | completed | GL-NCCN-PANC-2026, GL-ASCO-PANC-2016 | S |
| Urgent work-up of epigastric pain with weight loss, anemia and new diabetes: upper endoscopy within days, pancreas-protocol CT of the abdomen with CT of the chest, blood count, ferritin, liver tests, lipase and A1c; pantoprazole until the endoscopy; return at once for fresh black stools, fainting or yellow eyes | completed | GL-NCCN-PANC-2026, GL-NOEL-2019 | S |
| Intravenous iron for iron deficiency anemia from blood loss, with a blood count at each visit | completed | GL-NCCN-PANC-2026 | S |
| Tissue and staging: EUS-guided biopsy with extra cores for molecular profiling, biliary drainage with a metal stent, CA 19-9 after the bilirubin is normal, and review at the pancreatic tumor board | completed | GL-NCCN-PANC-2026, GL-ASCO-PANC-2016 | S |
| Germline genetic testing with counseling for every patient with pancreatic cancer, and tumor molecular profiling (including KRAS, BRCA1, BRCA2, PALB2, mismatch repair, NTRK and NRG1); cascade testing offered to blood relatives only if a germline variant is found | completed | GL-NCCN-PANC-2026, GL-ASCO-PANCGERM-2019, GL-ASCO-MPC-2020 | S |
| Modified FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, leucovorin 400 mg/m2, fluorouracil 2400 mg/m2 over 46 hours) every two weeks for six cycles (three months) before surgery through a port, with pegfilgrastim, olanzapine-based antiemetic prevention that spares dexamethasone because of her diabetes, loperamide for late diarrhea, and neuropathy checks; CA 19-9 every two cycles and restaging CT after four and six cycles; hepatitis B, hepatitis C and HIV screening and a pregnancy test first | completed | GL-NCCN-PANC-2026, GL-ASCO-PANC-2016, GL-ASCO-PANC-2019, GL-ASCO-ANTIEMETIC-2020, GL-ASCO-CIPN-2020, GL-ASCO-HBV-2020 | S |
| Palliative care from the day of diagnosis, alongside cancer treatment: symptom control, a serious illness conversation, and planning that keeps her writing at the center; oxycodone 5 mg as needed with a bowel regimen, and EUS-guided celiac plexus neurolysis if pain becomes severe | completed | GL-ASCO-PALL-2024, GL-NCCN-PANC-2026 | S |
| Nutrition: dietitian review at each phase, pancrelipase with every meal and snack, small frequent meals, weight at every visit | completed | GL-NCCN-PANC-2026 | S |
| Diabetes due to pancreatic disease: home glucose checks, A1c every three months, glucose checks before each cycle; insulin rather than oral agents if treatment is needed after surgery; dilated eye examination and urine albumin-to-creatinine ratio at diagnosis | completed | GL-ADA-2026, GL-CMID-2026 | S |
| Venous thromboembolism: Khorana score recorded (3: pancreatic primary and hemoglobin below 10 g/dL); prophylactic apixaban offered once the duodenal bleeding has settled; enoxaparin for four weeks after surgery | completed | GL-ASCO-VTE-2023, GL-AVERT-2019 | S |
| Fertility and contraception: oncofertility counseling before chemotherapy, a pregnancy test before treatment, and effective non-estrogen contraception if she becomes sexually active during treatment | completed | GL-ASCO-FERT-2018 | S |
| Pylorus-preserving pancreaticoduodenectomy with resection of the involved segment of the superior mesenteric vein after restaging shows no progression | completed | GL-NCCN-PANC-2026, GL-ASCO-PANC-2016 | S |
| Chemotherapy after surgery to complete about six months of treatment: six cycles of fluorouracil, leucovorin and irinotecan every two weeks, without oxaliplatin because of neuropathy; insulin glargine adjusted to home glucose readings; apixaban prophylaxis resumed during chemotherapy; surveillance afterwards with history, examination, CA 19-9 and CT every three to six months for two years | completed | GL-NCCN-PANC-2026, GL-ASCO-PANC-2016, GL-ASCO-PANC-2019, GL-ASCO-VTE-2023 | S |
| Distress and depression screening at each visit, plain explanations with written information, and support she chooses; she decides who is told and who receives each note | completed | GL-USPSTF-DEP-2023, GL-ASCO-PALL-2024 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Endoscopy and pancreas-protocol CT within one week, tissue diagnosis and biliary drainage within two weeks, and a tumor board plan within three weeks of presentation | 2026-05-04 | completed | Endoscopy in two days, CT in three, EUS biopsy and stent in one week, tumor board in nine days, consultation at two weeks | S |
| Germline genetic testing with counseling and tumor molecular profiling resulted before surgery | 2026-06-29 | completed | Germline panel negative; tumor KRAS G12D, microsatellite stable, no targetable alteration | S |
| Six cycles of modified FOLFIRINOX before surgery with no delay of more than one week | 2026-08-10 | completed | Six cycles; one dose reduction of irinotecan after diarrhea; CT shows a partial response | S |
| Resection with clear margins if restaging shows no progression | 2026-10-05 | completed | Pancreaticoduodenectomy with vein resection; margins clear (R0) | S |
| Pain 3 out of 10 or less with a clear head for writing | 2026-06-29 | completed | Pain 1 to 2 out of 10 on oxycodone 5 mg once or twice a day | S |
| Weight kept within 5 percent of the weight at diagnosis through chemotherapy, with enzyme replacement and dietitian support | 2026-08-10 | completed | Weight 54.2 kg before surgery, 2 percent below the weight at diagnosis | S |
| PHQ-9 below 10 throughout treatment, with support she chooses and palliative care alongside cancer treatment | 2026-10-05 | completed | PHQ-9 between 6 and 8 | S |